Recombinant Human CLEC12A protein(His75-Ala275), His-tagged

• Cat.No.: CLEC12A-6910H
• Product Overview: Recombinant Human CLEC12A (EAW96132.1) (His 75-Ala 275) was expressed in HEK293, with a polyhistidine tag at the N-terminus.

Specification

• Species: Human
• Source: HEK293
• Tag: His
• Protein Length: 75-275 a.a.
• Form: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
• Molecular Mass: The recombinant human CLEC12A consists of 221 amino acids and has a calculated molecular mass of 26 kDa. The apparent molecular mass of rhCLEC12A is approximately 40-45 kDa in SDS-PAGE under reducing conditions.
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Purity: > 95 % as determined by SDS-PAGE
• Storage: Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Gene Information

• Gene Name: CLEC12A C-type lectin domain family 12, member A [ Homo sapiens ]
• Official Symbol: CLEC12A
• Synonyms: CLEC12A; C-type lectin domain family 12, member A; C-type lectin domain family 12 member A; CLL 1; MICL; C-type lectin superfamily; C-type lectin protein CLL-1; C-type lectin-like molecule-1; dendritic cell-associated lectin 2; myeloid inhibitory C-type lectin-like receptor; CLL1; CLL-1; DCAL-2; MGC70602
• Gene ID: 160364
• mRNA Refseq: NM_001207010
• Protein Refseq: NP_001193939
• MIM: 612088
• UniProt ID: Q5QGZ9

Case Study

Case 1: Tang H, et al. J Biol Chem. 2024

CLEC12A is part of the C-type lectin receptor family and helps keep our immune system in balance by recognizing MSU crystals from dead cells. Researchers are still figuring out exactly how this works, but we’ve found some important details. They have studied the structure of the CLEC12A domain and found a specific "basic patch" that’s key for binding these crystals. By using advanced techniques, they measured how strong this bond is. CLEC12A also groups together on the cell surface, possibly acting like a receptor that pulls in MSU crystals. This helps us understand how CLEC12A and MSU crystals interact.

Fig1. THP-1 macrophages were stained with CLEC12A-PE (stained control) or treated with MSU crystals and stained with CLEC12A-PE.

Fig2. Both wild-type and CLEC12A-CTLD mutant proteins were used to perform CD spectrometry.

Case 2: Paré G, et al. Front Immunol. 2021

CLEC12A helps control neutrophil activity and inflammation, especially in arthritis. Researchers found that activating CLEC12A moves it to certain cell membrane areas and triggers phosphorylation. This affects pathways like MAPKs and JAK-STAT. When neutrophils encounter uric acid crystals (a gout trigger), it leads to overactive p38 and Akt pathways, but CLEC12A steps in to manage IL-8 release through p38/PI3K-Akt. This insight might be key to reducing inflammation in therapy.

Fig1. CLEC12A is phosphorylated upon its antibody-induced translocation to the flotillin-rich, detergent-insoluble cell pellet.

Fig2. CLEC12A was cross-linked on neutrophils with 50C1 prior to MSU stimulation and cell lysates.

Application

Recombinant CLEC12A protein is making waves in research and therapy because it helps regulate the immune system. It's particularly useful for studying inflammatory conditions like arthritis. Scientists use this protein to see how it impacts immune cell behavior and keeps inflammation in check, which could lead to new treatments for chronic issues and help tame those immune responses. In drug development, recombinant CLEC12A is a big help. It allows researchers to test new drugs aimed at fine-tuning immune pathways. By understanding how CLEC12A interacts with these pathways, they can design meds that control immune reactions with fewer side effects. This makes CLEC12A a key player in finding treatments for autoimmune problems. Plus, recombinant CLEC12A is a handy tool for unraveling cell signaling mysteries. It helps scientists uncover how cells communicate within the immune system, pushing our understanding further. This insight is crucial for innovating new diagnostic methods and treatment strategies across different diseases.

Fig1. Signal transduction pathways potentially regulated by CLEC12A. (Kenneth R McLeish, 2023)